Lundbeck says the last patient has been randomized in DEEp OCEAN, a global Phase III trial evaluating bexicaserin for seizures associated with developmental and epileptic encephalopathies (DEEs). The company describes DEEs as a diverse group of childhood-onset epilepsies. According to the announcement, the study is designed to assess bexicaserin in patients across a wide range of DEE syndromes, with most participants belonging to multiple or broader DEE categories rather than a single condition. Lundbeck presents DEEp OCEAN as the broadest pivotal trial to date for this research program. With randomization completed, the trial moves forward toward subsequent study stages and data collection. No results from efficacy or safety are reported in the provided release. The announcement is framed as a milestone in the Phase III program for bexicaserin and indicates continued enrollment operations are no longer part of the trial’s conduct, since the final participant has been assigned to the study arms.